The cost of We­govy: $1.1M to pre­vent one ma­jor car­dio­vas­cu­lar event, Airfin­i­ty says

The im­pact of No­vo Nordisk’s GLP-1 semaglu­tide on car­dio­vas­cu­lar health was re­ceived with great fan­fare ear­li­er this month, with the Dan­ish phar­ma tout­ing a 20% re­duc­tion in ma­jor ad­verse car­dio­vas­cu­lar events (MACE) by 20% in obese or over­weight pa­tients with­out di­a­betes in its vast SE­LECT tri­al.

But a new analy­sis from dis­ease fore­cast­ing com­pa­ny Airfin­i­ty says that the price tag to ac­tu­al­ly pre­vent one heart at­tack, stroke or car­dio­vas­cu­lar death could be $1.1 mil­lion, even af­ter a 65% re­bate on the list price.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.